Report – Intas Pharmaceuticals’ Troubles with FDA Continue

This report discusses the Warning Letter given to Intas Pharmaceuticals, which focuses on data integrity and the failure of management to fulfill specific responsibilities. Additional content added on November 15, 2023, shows how Redica Systems Red Flag Model predicted these issues and how you can use this analysis in the future.